Back

Outcomes of empagliflozin versus dapagliflozin treatment in patients with heart failure based on left ventricular ejection fraction: a multicentre cohort study

1 September 2025 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (4) - Pharmacotherapy for heart failure (2) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Hyo-Suk Ahn

Uijeongbu St. Mary's Hospital, Seoul (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Ms E. Lozo (Zagreb, HR)
Abstract Slides Video
Presentation thumbnail
Doctor E. Merkel (Budapest, HU)
Abstract
Presentation thumbnail
Mr A. Caamano Noya (Santiago de Compostela, ES)
Abstract Slides Video
Presentation thumbnail
Mr E. Boada Lincango (A Coruna, ES)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (4) - Pharmacotherapy for heart failure (2)

The Event

Event poster

ESC Congress 2025

1 September 2025 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Comparative outcomes between empagliflozin and dapagliflozin in heart failure: real world multi-center cohort study
thumbnail
Congress Presentation
Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction
thumbnail
Congress Presentation
A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources